Metraipolis › archive › dc_49effbee2b3a

Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase — Europe PMC PMID:41879439

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41879439
DOI: 10.2174/011570159x448901251228053318
License (as archived): solo-consultazione
Archived: 2026-11-07T04:17:14.918Z
SHA-256 of the archived text: 846d3499323305c69a411248f334b4d6c6a278c5973c24a40679da6b053804b8
Stable URL of this page: https://metraipolis.com/documento/dc_49effbee2b3a

How to cite

Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase — Europe PMC PMID:41879439 — Europe PMC (en), https://europepmc.org/article/MED/41879439 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_49effbee2b3a (Metraipolis archive dc_49effbee2b3a, sha256 846d3499323305c69a411248f334b4d6c6a278c5973c24a40679da6b053804b8)

BibTeX

@misc{dc49effbee2b3a,
  title = {Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase — Europe PMC PMID:41879439},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41879439},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_49effbee2b3a; sha256 846d3499323305c69a411248f334b4d6c6a278c5973c24a40679da6b053804b8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41879439. Agents can read the archived copy with the MCP tool read_document.